Proteomics International Laboratories Ltd
Research Proteomics International Laboratories Ltd (PIQ) on Bullrun: market cap AUD 23.15M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPIQ
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 23.15M
- Financial periodFY2025
- RevenueAUD 960.39K
- Revenue growth7.6%
- Net income-AUD 8.11M
- Free cash flow-AUD 6.63M
- Gross margin100.0%
Valuation Snapshot
latest market cap is AUD 23.15M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 960.39K | -AUD 8.11M | -AUD 6.63M | 100.0% | -0.06 | AUD 11.04M | AUD 277.74K | AUD 13.17M |
| FY2024 | AUD 892.14K | -AUD 6.38M | -AUD 6.00M | 100.0% | -0.05 | AUD 6.64M | AUD 316.40K | AUD 9.41M |
| FY2023 | AUD 730.34K | -AUD 6.18M | -AUD 6.91M | 100.0% | -0.05 | AUD 6.03M | AUD 64.09K | AUD 8.38M |
| FY2022 | AUD 1.49M | -AUD 4.97M | -AUD 3.67M | 100.0% | -0.05 | AUD 2.11M | n/a | AUD 3.39M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-13 | AUD 23.15M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, and India. It provides PromarkerD, a blood test to predict chronic kidney disease in people with type 2 diabetes. The company's products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Proteomics International Laboratories Ltd's market cap?
Proteomics International Laboratories Ltd's market capitalization is AUD 23.15M.
What does Proteomics International Laboratories Ltd do?
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, and India. It provides PromarkerD, a blood test to predict chronic kidney disease in people with type 2 diabetes.